Drugs / OMPEKIMIG
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06712082 | Feb → Sep 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05496738 | Aug 2022 → May 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05995964 | Aug 2023 → Oct 2026 expected | atopic eczema | Pfizer | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Pfizer | Results Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis pfizer.com ↗
Stage 1 has concluded and both tilrekimig and ompekimig groups met the primary endpoint. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | Pfizer | Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis pfizer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMPEKIMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068473 ↗ |
| Known as | PF-07264660 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06712082 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068473 ↗ |
| Route | Intravenous | “PF-07264660 will be administered intravenously” NCT05496738 ↗ |